The designation establishes a quantifiable threshold in global immunisation procurement, enabling distribution through international vaccine alliances serving lower-income countries.
Regulatory threshold and clinical evidence
The product, marketed as Abrysvo by Pfizer, is administered during the third trimester of pregnancy. Transplacental antibody transfer generates passive immunity in the infant through approximately six months of life.
Phase 3 clinical trial data evaluated by the European Medicines Agency established 81.8% efficacy against severe RSV-associated lower respiratory tract disease within the first 90 days post-birth. Efficacy measured 69.4% through the six-month endpoint. These figures derive from pivotal trials conducted across high- and low-income settings, per EMA assessment cited by Health Policy Watch.
Burden context and mitigation pathways
Respiratory syncytial virus ranks as the second leading cause of infant mortality globally, following malaria. The WHO attributes over 100,000 annual deaths in children under five to RSV, with more than 97% concentrated in low- and middle-income countries. Sub-Saharan Africa carries a disproportionate burden, compounded by limited access to specialised respiratory care.
Gavi, the Vaccine Alliance, confirmed acceptance of the WHO determination and indicated eligible low-income countries may now apply for funding to integrate maternal immunisation into routine healthcare delivery. The multi-dose presentation reduces cold-chain expenditure and logistical variance relative to single-dose alternatives, a mitigation factor for resource-constrained systems. Vaccine development received support from the Gates Foundation.
Pharmacovigilance posture
Post-authorisation surveillance in the United States has tracked preterm birth incidence among vaccinated mothers. Reported rates demonstrated no statistically significant variance from background thresholds, per Health Policy Watch. Routine post-marketing surveillance continues across European and US jurisdictions.
The EMA authorised Abrysvo on a determination indicating protective benefit substantially exceeds documented risk. Continued surveillance remains the principal instrument for detecting rare or delayed adverse signals that registration trials may have lacked statistical power to identify. The vaccine operates alongside monoclonal antibody therapies, which deliver direct passive protection postnatally; maternal immunisation confers immunity in utero, expanding the preventive matrix available to health systems.
Risk assessment
The WHO prequalification resolves a procurement barrier. It does not resolve implementation variance, which remains the primary determinant of population-level efficacy in target regions. Surveillance continuity across diverse populations constitutes the indispensable control for any subsequent safety variance. Practitioners integrating maternal RSV vaccination should confirm product presentation, gestational timing window, and concurrent pharmacovigilance reporting obligations under their jurisdictional framework.